Why? Fasting is a common strategy during GLP-1 therapy, but hunger during fasting periods can derail progress
That is where confusion starts for many patients
While facilities making compounded medications are strictly regulated for certain quality practices, the compounded medications themselves are not approved or evaluated by the FDA for safety, effectiveness, or quality
In their separate Phase 2 trials, retatrutide monotherapy showed larger weight loss (~24.2% at 48 weeks, 12 mg) than standalone cagrilintide (~10.8% at 26 weeks, 4.5 mg), and indirect network meta-analyses rank retatrutide highly
depression was not a prominently reported adverse event in published data
One section of the warning label links the possibility of AKI to severe dehydration from gastrointestinal distress like vomiting and diarrhea